SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Indoco Remedies - Quaterly Results

23 Jul 2024 Evaluate
A decrease in the sales to Rs. 4014.30 millions was observed for the quarter ended June 2024. The sales stood at Rs. 4228.80 millions during the similar quarter previous year.Net profit of the cmpany stood at Rs. 149.50 millions for the quarter ended June 2024 a decline of -42.37% from Rs. 259.40 millions  in the same quarter last year.The Operating Profit of the company witnessed a decrease to 550.90 millions from 633.20 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202406 202306 % Var 202406 202306 % Var 202403 202303 % Var
Sales 4014.30 4228.80 -5.07 4014.30 4228.80 -5.07 17908.10 16666.90 7.45
Other Income 35.20 4.10 758.54 35.20 4.10 758.54 85.10 23.30 265.24
PBIDT 550.90 633.20 -13.00 550.90 633.20 -13.00 2664.90 2872.20 -7.22
Interest 118.80 77.80 52.70 118.80 77.80 52.70 368.20 250.30 47.10
PBDT 432.10 555.40 -22.20 432.10 555.40 -22.20 2412.00 2621.90 -8.01
Depreciation 237.00 198.70 19.28 237.00 198.70 19.28 879.80 706.00 24.62
PBT 195.10 356.70 -45.30 195.10 356.70 -45.30 1532.20 1915.90 -20.03
TAX 45.60 97.30 -53.13 45.60 97.30 -53.13 365.80 502.30 -27.17
Deferred Tax -1.70 11.80 -114.41 -1.70 11.80 -114.41 38.10 -49.70 -176.66
PAT 149.50 259.40 -42.37 149.50 259.40 -42.37 1166.40 1413.60 -17.49
Equity 184.40 184.30 0.05 184.40 184.30 0.05 184.40 184.30 0.05
PBIDTM(%) 13.72 14.97 -8.35 13.72 14.97 -8.35 14.88 17.23 -13.65

Indoco Remedies Share Price

215.85 5.05 (2.40%)
05-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1820.75
Dr. Reddys Lab 1270.95
Cipla 1333.55
Zydus Lifesciences 911.85
Lupin 2343.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×